The observation that AngII-induced hypertension is significantly blunted in the absence of SPAK activity supports the proposal that strategies preventing SPAK–NCC interactions could be a new therapeutic avenue for hypertension [31]. This evidence concerns the gene SLC12A3 and hypertensive disorder.